1). Nachman JB., Sather HN., Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. New Eng J Med. 1998. 388:1663–71.
Article
2). Reiter A., Schrappe M., Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994. 84:3122–33.
Article
3). Gajjar A., Ribeiro R., Hancock ML, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1995. 86:1292–5.
Article
4). Steinherz PG., Gaynon PS., Breneman JC, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia-the importance of early marrow response: report from the Children's Cancer Group. J Clin Oncol. 1996. 14:389–98.
Article
5). Park DY., Yang CH., Park SH., Lyu CJ., Kim KY. Prognostic significance of circulating blasts after 7 day of multiagent chemotherapy in childhood acute lymphoblastic leukemia. Korean J Pediatr Hematol-Oncol. 1999. 6:293–7.
6). Gaynon PS., Bleyer WA., Steinherz PG, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol. 1990. 18:273–9.
Article
7). Schultz KR., Massing B., Spinelli JJ., Gaynon PS., Wadsworth L. Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1997. 29:16–22.
Article
8). Gaynon PS., Trigg ME., Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000. 14:2223–33.
Article
9). Nachman J., Sather HN., Cherlow JM, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol. 1998. 16:920–30.
Article
10). Simone JV. Childhood leukemia-successes and challenges for survivors. N Engl J Med. 2003. 349:627–8.
11). Schultz KR., Pullen DJ., Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007. 109:926–35.
Article
12). Jacquillat C., Weil M., Gemon MF, et al. Combination therapy in 130 patients with acute lymphoblastic leukemia (Protcol 06 LA 66-Paris). Cancer Res. 1973. 33:3278–84.
13). Tubergen D., Gilchrist GS., O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children's Cancer Group phase III trial. J Clin Oncol. 1993. 11:527–37.
Article
14). Nachman J., Sather HN., Gaynon PS., Lukens JN., Wolff L., Trigg ME. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol. 1997. 15:2222–30.
Article
15). Seibel NL., Steinherz PG., Sather HN., Lukens JN., Wolff L., Trigg ME. Early post-induction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008. 111:2548–55.
16). Kang HJ., Shin HY., Ahn HS. Acute lymphoblastic leukemia in children: past, present and future. Korean J Pediatr. 2007. 50:601–5.
Article
17). Na SO., Shin HY., Ahn HS., Park SK. Study on the treatment of childhood acute lymphoblastic leukemia. J Korean Cancer Assoc. 1992. 24:390–400.